Plasma Growth Hormone as a Prognostic Biomarker to Durvalumab and Tremelimumab in Patients with Advanced Hepatocellular Carcinoma

Shadi Chamseddine,Michael LaPelusa,Lianchun Xiao,Yehia Mohamed,Sunyoung Lee,Zishuo Hu,Rikita Hatia,Manal Hassan,James Yao,Dan Duda,Saumil Datar,Hesham Amin,Ahmed Kaseb

DOI: https://doi.org/10.2147/jhc.s452564

2024-03-05

Journal of Hepatocellular Carcinoma

Abstract:Shadi Chamseddine, 1, &ast Michael LaPelusa, 2, &ast Lianchun Xiao, 3 Yehia I Mohamed, 1 Sunyoung S Lee, 1 Zishuo Ian Hu, 1 Rikita I Hatia, 4 Manal Hassan, 4 James C Yao, 1 Dan G Duda, 5 Saumil Datar, 6 Hesham M Amin, 7, 8 Ahmed O Kaseb 1 1 Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; 2 Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; 3 Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; 4 Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; 5 Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA; 6 Department of Internal Medicine, University of Texas Health Science Center at Houston, Houston, TX, USA; 7 Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; 8 MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences, Houston, TX, USA &astThese authors contributed equally to this work Correspondence: Hesham M Amin, Department of Hematopathology, The University of Texas MD Anderson Cancer Center, MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences Houston, TX, 77030, USA, Tel +1 713 794-1769, Fax +1 713 792-7273, Email Ahmed O Kaseb, Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA, Tel +1-713-792-2828, Fax +1 713-745-1163, Email Introduction: In this study, we explored the potential of plasma growth hormone (GH) as a prognostic biomarker in patients with advanced HCC treated with durvalumab plus tremelimumab (D+T). Methods: In this study, we included 16 patients with advanced HCC who received D+T at MD Anderson Cancer Center between 2022 and 2023 and had plasma GH measurements recorded before treatment. Plasma GH levels were measured from prospectively collected blood samples and were correlated with progression-free survival (PFS) and overall survival (OS). The cutoff for normal GH levels in women and men was defined as ≤ 3.7 μg/L and ≤ 0.9 μg/L, respectively. The Kaplan–Meier method was employed to compute the median OS and PFS, while the Log rank test was applied to compare the survival outcomes between the GH-high and GH-low groups. Results: Sixteen patients were included in this analysis, two female and fourteen male, with a median age of 65.5 years. At the time of the analysis, the 6-month OS rate was 100% among GH-low patients (6 patients) and 30% among GH-high patients (10 patients). OS was significantly longer in GH-low patients (not evaluable) compared to GH-high patients (3.94 months) (p = 0.030). PFS was also significantly longer in GH-low patients (not evaluable) compared to the GH-high patients (1.87 months) (p = 0.036). Conclusion: Plasma GH is a prognostic biomarker in patients with advanced HCC treated with D+T. Given the relatively small patient cohort size, this finding should be further validated in larger randomized clinical trials in advanced HCC patients. Keywords: hepatocellular carcinoma, growth hormone, durvalumab, tremelimumab, overall survival, progression-free survival Globally, hepatocellular carcinoma (HCC) is the third leading cause of cancer-related mortality. 1–3 More than 80% of patients with HCC are diagnosed at an advanced stage. 4 Most patients ultimately require systemic therapy as a consequence of being diagnosed with unresectable disease or recurrence after resection and locoregional therapies. 5 Prior to 2020, multikinase inhibitors were approved as first-line treatment options for patients with unresectable HCC. 6 Since then, the combination of atezolizumab, an antibody against programmed death-ligand 1 (PD-L1), plus bevacizumab, an antibody against vascular endothelial growth factor (VEGF), was shown to improve overall survival (OS) compared to sorafenib, a multikinase inhibitor, among patients with untreated advanced HCC in the Phase III IMbrave 150 trial. 7 Soon after, the STRIDE regimen, which combines tremelimumab, an antibody against cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), with durvalumab, an antibody against programmed death-ligand 1 (PD-1), successfully achieved its primary endpoint of demonstrating a statistically significant improvement in OS when compared to sorafenib in patients with untrea -Abstract Truncated-

oncology